Independent biotech consultants commissioned to report on Oraxol clinical data of belief Athenex will not receive New Drug Application from FDA. November 13, 2019 – Viceroy commissioned a report from a highly reputable, independent biotech consulting firm into the prospective New Drug Application (NDA) approval
Falling revenues, stalled operations, flat R&D. DOWNLOAD BRIEF November 7, 2019 – This report is a brief on Athenex’s Q3 results announcement. Viceroy will provide a further, more in depth update upon the release of Athenex’s 10-Q. Athenex revenues continue to fall Q/Q, and has
Ahead of this week’s earnings, Viceroy provide an insight of what’s to come. REPORT DOWNLOAD LINK Athenex Inc. v. Azar – Summary November 4, 2019 – This report provides a deep dive on Athenex’s significant revenue declines and capital over-commitment that investors can expect in
While his resume appears impressive, Athenex Chief Operating Officer Jeffrey Yordon has always been in the proximity of disaster, including two class action lawsuits. REPORT DOWNLOAD LINK October 29, 2019 – As we move into the sixth installment of our coverage on Athenex, Viceroy reiterate
Athenex recycle press releases to pump investors. Viceroy release details of further conflicts with Athenex CROs. REPORT DOWNLOAD LINK October 28, 2019 – This report will continue to touch on major Athenex conflict of interest issues. In another slap to the face for invetors, Athenex,
Buffalo Soldiers vs the system, and a summary of Viceroy’s reports this week. REPORT DOWNLOAD LINK October 25, 2019 – This report serves as a summary to Viceroy’s work over this week, alongside data we have collated on Athenex’s dealing with the NY State Government
Athenex management’s proliferation for fraud precedes them. REPORT DOWNLOAD LINK October 24, 2019 – Viceroy expose more managerial ties to established frauds, and address Athenex’s response to our previous work, which addresses absolutely nothing. Management’s response underestimates how many improprieties are recorded in the public
Athenex’s revenue generating business is a house of cards, muddled with further ties to large scale frauds, fabricated management credentials, and photoshopped offices. REPORT DOWNLOAD LINK October 23, 2019 – This follow up report focuses specifically on Athenex’s Polymed subsidiary, which accounts for a large
Poorly designed clinical study for flagship drug outdated since 2005. Meanwhile, Directors siphon large amounts of cash from shareholders. REPORT DOWNLOAD LINK October 22, 2019 – Viceroy Research is short Athenex, Inc. (NASDAQ: ATNX). Our research has found significant causes for concern in the company’s
July 17, 2019 – We ask investors today to consider what Viceroy believes is an excessive enrichment by Pareteum’s Executive Chairman and Principal Executive Officer’s share ownership and compensation: Reflect a low level of confidence in the company given Hal’s immediate offering of 2,000,000 shares
Viceroy Research LLC are an investigative financial research group registered in Delaware, USA.
Our research reports have been prepared for educational purposes only and expresses our opinions. Our reports and any statements made in connection with them are the authors’ opinions, which have been based upon publicly available facts, field research, information, and analysis through our due diligence process, and are not statements of fact. All expressions of opinion are subject to change without notice, and we do not undertake to update or supplement any reports or any of the information, analysis and opinion contained in them. We believe that the publication of our opinions about public companies that we research is in the public interest. We are entitled to our opinions and to the right to express such opinions in a public forum. You can access any information or evidence cited in this report or that we relied on to write this report from information in the public domain.
To the best of our ability and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and who are not insiders or connected persons of the stocks covered herein or who may otherwise owe any fiduciary duty or duty of confidentiality to the issuer. We have a good-faith belief in everything we write; however, all such information is presented “as is,” without warranty of any kind – whether express or implied.
In no event will we be liable for any direct or indirect trading losses caused by any information available on this report. Think critically about our opinions and do your own research and analysis before making any investment decisions. We are not registered as an investment advisor in any jurisdiction. By downloading, reading or otherwise using our research reports, you agree to do your own research and due diligence before making any investment decision with respect to securities discussed herein, and by doing so, you represent to us that you have sufficient investment sophistication to critically assess the information, analysis and opinions in this report. You should seek the advice of a security professional regarding your stock transactions.
This website, all documents contained herein or any information herein should not be interpreted as an offer, a solicitation of an offer, invitation, marketing of services or products, advertisement, inducement, or representation of any kind, nor as investment advice or a recommendation to buy or sell any investment products or to make any type of investment, or as an opinion on the merits or otherwise of any particular investment or investment strategy.
Any examples or interpretations of investments and investment strategies or trade ideas are intended for illustrative and educational purposes only and are not indicative of the historical or future performance or the chances of success of any particular investment and/or strategy.
You should assume that the authors have a direct or indirect interest/position in all stocks (and/or options, swaps, and other derivative securities related to the stock) and bonds covered herein, and therefore stand to realize monetary gains in the event that the price of either declines.
The authors may continue transacting directly and/or indirectly in the securities of issuers covered herein for an indefinite period and may be long, short, or neutral at any time hereafter regardless of their initial recommendation.